Long‐term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis
| Autor: | Valeria A. Sansone, Jeffrey Statland, Nicholas E. Johnson, Michael G. Hanna, Emma Ciafaloni, Fredric Cohen, Perry B Shieh, Robert C. Griggs |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Dichlorphenamide Physiology Placebo Gastroenterology Paralyses Familial Periodic Young Adult Cellular and Molecular Neuroscience Double-Blind Method Physiology (medical) Internal medicine Post-hoc analysis medicine Paralysis Humans Carbonic Anhydrase Inhibitors Adverse effect Aged business.industry Periodic paralysis Middle Aged medicine.disease Discontinuation Treatment Outcome Tolerability Female Neurology (clinical) medicine.symptom business |
| Zdroj: | Muscle & Nerve. 64:342-346 |
| ISSN: | 1097-4598 0148-639X |
| DOI: | 10.1002/mus.27354 |
| Popis: | INTRODUCTION/AIM Long-term efficacy and safety of dichlorphenamide (DCP) were characterized in patients with primary periodic paralysis (PPP). METHODS Patients with PPP in a double-blind, placebo-controlled study were randomly assigned to receive DCP 50 mg twice daily or placebo for 9 weeks, followed by a 52-week open-label DCP treatment phase (DCP/DCP and placebo/DCP populations). Efficacy (attack rate, severity-weighted attack rate) and safety were assessed in patients completing the study (61 weeks). In this post hoc analysis, efficacy and safety data were pooled from hyperkalemic and hypokalemic substudies. RESULTS Sixty-three adults (age, 19-76 years) completed the double-blind phase; 47 (74.6%) of these patients completed 61 weeks. There were median decreases in weekly attack and severity-weighted attack rates from baseline to week 61 (DCP/DCP [n = 25], -1.00 [P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text